Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 8:78:103961.
doi: 10.1016/j.amsu.2022.103961. eCollection 2022 Jun.

Two cases of Erythrodermic psoriasis treated with Golimumab

Mayssoun Kudsi  1   2 , Mhd Amin Alzabibi  1 , Mosa Shibani  1
Affiliations

Two cases of Erythrodermic psoriasis treated with Golimumab

Mayssoun Kudsi et al. Ann Med Surg (Lond). .

Abstract

Introduction and importance: Erythrodermic psoriasis (EP) is a very severe subtype of psoriasis, with a challenge poses in its treatment, as currently available therapies often provide unsatisfactory results, for those many biologics have been used in the treatment of EP such as Golimumab which has been extensively studied for the treatment of psoriatic arthritis, and chronic plaque psoriasis. However, no clinical trials have been performed for EP.

Case presentation: We report two cases of a 23-year old female, and a 31-year male who presented with severe psoriasis that previously un respond to ultraviolet B phototherapy, methotrexate, cyclosporine, and topical agents. Skin lesions worsened progressively and developed into erythroderma. Therefore, we administered golimumab 50 mg, which lead to the improvement of the skin lesions according to the Psoriasis Area and Severity Index score after the first administration; lesions improved further throughout the treatment course.

Conclusion: Golimumab may be an alternative treatment for Erythrodermic psoriasis patients unrespond to other treatments even it did not have the FDA approval, so this is an off label indication and treatment.

Keywords: Biological products; Case series; Erythrodermic psoriasis; Golimumab.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Erythematosus psoriasis, presented in a 23-year-old female.
Fig. 2
Fig. 2
Erythematosus psoriasis, presented in a 31-year-old male.
See this image and copyright information in PMC

References

    1. Rosenbach M., Hsu S., Korman N.J., Lebwohl M.G., Young M., Bebo B.F., Jr., Van Voorhees A.S. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 2010;62(4):655–662. - PubMed
    1. Lebwohl M. Psoriasis. Lancet (London, England) 2003;361(9364):1197–1204. - PubMed
    1. Hawilo A., Zaraa I., Benmously R., Mebazaa A., El Euch D., Mokni M., Ben Osman A. [Erythrodermic psoriasis: epidemiological clinical and therapeutic features about 60 cases] La Tunisie medicale. 2011;89(11):841–847. - PubMed
    1. Zhang P., Chen H.X., Duan Y.Q., Wang W.Z., Zhang T.Z., Li J.W., Tu Y.T. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J. Huazhong Univ. Sci. Technol. 2014;34(4):596–601. Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban. - PubMed
    1. Deeva I., Mariani S., De Luca C., Pacifico V., Leoni L., Raskovic D., Kharaeva Z., Korkina L., Pastore S. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine. 2010;49(2):163–170. - PubMed